KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) EBITDA: 2018-2025

Historic EBITDA for Aurinia Pharmaceuticals (AUPH) over the last 8 years, with Sep 2025 value amounting to $31.7 million.

  • Aurinia Pharmaceuticals' EBITDA rose 113.89% to $31.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.5 million, marking a year-over-year increase of 452.31%. This contributed to the annual value of $5.8 million for FY2024, which is 107.51% up from last year.
  • Aurinia Pharmaceuticals' EBITDA amounted to $31.7 million in Q3 2025, which was up 47.94% from $21.4 million recorded in Q2 2025.
  • Over the past 5 years, Aurinia Pharmaceuticals' EBITDA peaked at $31.7 million during Q3 2025, and registered a low of -$50.4 million during Q1 2021.
  • For the 3-year period, Aurinia Pharmaceuticals' EBITDA averaged around $404,727, with its median value being $717,000 (2024).
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' EBITDA slumped by 313.43% in 2021, and later surged by 2,889.26% in 2025.
  • Aurinia Pharmaceuticals' EBITDA (Quarterly) stood at -$33.4 million in 2021, then grew by 23.37% to -$25.6 million in 2022, then decreased by 4.21% to -$26.7 million in 2023, then surged by 104.38% to $1.2 million in 2024, then skyrocketed by 113.89% to $31.7 million in 2025.
  • Its EBITDA stands at $31.7 million for Q3 2025, versus $21.4 million for Q2 2025 and $23.2 million for Q1 2025.